# OnCo record paper-schettini-her2-low-features-npj-breast-cancer-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-schettini-her2-low-features-npj-breast-cancer-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-schettini-her2-low-features-npj-breast-cancer-2021" ;
  schema:name "Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer"@en ;
  schema:description "A 3,689-patient study showing that 36.6 percent of triple-negative tumours are HER2-low, that in triple-negative disease HER2-low tumours are biologically no different from HER2-zero ones, and that pathologists agree poorly on the score; the label matters only because a drug now depends on it."@en ;
  schema:url <https://onco.cc/key-papers/paper-schettini-her2-low-features-npj-breast-cancer-2021/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41523-020-00208-2>, <https://pubmed.ncbi.nlm.nih.gov/33397968/> ;
  onco:tag "tnbc-evidence" ;
  schema:sameAs <https://doi.org/10.1038/s41523-020-00208-2> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Schettini F, Chic N, Brasó-Maristany F, et al." ;
  onco:related <https://onco.cc/key-papers/paper-destiny-breast04-nejm-2022/>, <https://onco.cc/biomarkers/her2-low-ihc/> ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/her2-low-metastatic-breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/digital-pathology-ai/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-deruxtecan/> ;
  onco:terms <https://onco.cc/terms/her2-low/>, <https://onco.cc/biomarkers/her2-ultralow/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/pam50/> ;
  onco:trials <https://onco.cc/trials/destiny-breast04/> ;
  onco:people <https://onco.cc/people/aleix-prat/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/> .